ソフィオンバイオサイエンス Official site

Discovery of epilepsy treatment drug from spider venom peptides.

I learned how to develop protocols for the study of Kv7 channels.

Our company is jointly developing a new protocol that enables efficient screening studies to identify modulators of Kv7.2/Kv7.3 channel activity using spider venom peptides. This will advance the understanding of gain-of-function mutations in channel-related epilepsy and potential therapies. *For more details, please refer to the related links. Feel free to contact us for more information.*

Related Link - https://sophion.co.jp/can-peptides-from-spider-ven…

basic information

*You can view the detailed content of the article through the related link. For more information, please feel free to contact us.*

Price range

Delivery Time

Applications/Examples of results

*You can view the detailed content of the article through the related link. For more information, please feel free to contact us.*

Auto Patch Clamp System "Qube384"

PRODUCT

Semi-Automatic Patch Clamp System "QPatch Compact"

PRODUCT

Automated Patch Clamp System "QPatch II"

PRODUCT

News about this product(1)

Recommended products

Distributors

Sophion Bioscience was founded by a passionate group of electrophysiologists with a common goal of providing objective patch clamp results quickly and accurately, independent of the experimenter's skill. We have grown from a small startup in Denmark to a global company, but our passion and commitment to providing high-performance patch clamp solutions remain unchanged. Through exceptional technical service and application support, we back our customers in achieving their goals. Additionally, with the continuous development of the QPatch and Qube platforms, we ensure uncompromising data quality in a user-friendly environment, from assay setup to data analysis.